fda-and-biotech News
Kura Oncology Secures $30M Payment Advancing Key Leukemia Drug
Milestone from partner Kyowa Kirin triggered by start of pivotal Phase 3 trial for ziftomenib in frontline acute myeloid leukemia, bolstering the company's finances.
iBio Secures $15M Financing, Granting Key Investor a Board Seat
The deal gives Lynx1 Capital Management the right to nominate a director, signaling a significant vote of confidence in the biotech's strategy.
Viking Therapeutics Surges Over 10% on Oral Obesity Drug Trial Results
Positive Phase 2 data for its GLP-1 drug candidate VK2735 overshadows a wider-than-expected quarterly loss, fueling investor optimism.
Harmony Biosciences Reaffirms Guidance on WAKIX Strength
Strong sales of the company's flagship narcolepsy drug are offsetting recent pipeline disappointments, keeping its 2025 outlook intact.
Tango Therapeutics Secures $225M to Advance Cancer Drugs
Financing led by major institutional investors strengthens the company's balance sheet and extends its operational runway for its precision oncology pipeline.
Moderna Shares Tumble as CMV Vaccine Trial Fails Key Endpoint
The company is discontinuing its development program for the congenital CMV vaccine, a significant setback for its non-COVID product pipeline.
Arcturus Stock Collapses 52% After Cystic Fibrosis Drug Disappoints
The mRNA-based therapy failed to meet its primary lung function endpoint in a Phase 2 trial, erasing over $650 million in market value despite some encouraging secondary data.
Novartis Drug Cosentyx Succeeds in New Phase 3 Trial
Success in treating polymyalgia rheumatica could expand the label for the blockbuster immunology drug, targeting an underserved elderly patient population.